Table 1.
Characteristics of 28 Participantsa
| Variable | Median | 25%–75% Percentiles | Range |
|---|---|---|---|
| Sociodemographic characteristics | |||
| Age, y | 71.00 | 65.25–75.00 | 57.00–80.00 |
| PD duration, y | 12.50 | 7.25–17.75 | 3.00–30.00 |
| LEDD, mg | 815.00 | 539.00–1119.50 | 62.00–2041.50 |
| Severity of PD | |||
| Hoehn and Yahr stage | 2.00 | 1.50–2.00 | 1.50–3.00 |
| MDS-UPDRS I | 13.00 | 9.00–17.75 | 7.00–30.00 |
| MDS-UPDRS II | 21.00 | 17.25–25.00 | 10.00–32.00 |
| MDS-UPDRS III while off medication | 46.50 | 35.25–52.00 | 31.00–55.00 |
| MDS-UPDRS III while on medication | 34.50 | 25.50–40.25 | 10.00–62.00 |
| MDS-UPDRS IV | 4.50 | 3.00–10.00 | 0.00–13.00 |
| Quality of life | |||
| PD Questionnaire, 8-item version | 34.38 | 28.13–40.63 | 6.25–65.63 |
| Life-Space Assessment (n = 24) | 84.00 | 73.50–92.00 | 35.00–120.00 |
| Fear/fall risk | |||
| Parkinson Anxiety Scale | 14.50 | 7.25–19.00 | 2.00–21.00 |
| Falls Efficacy Scale–International | 32.00 | 26.25–39.25 | 19.00–59.00 |
| Cognitive function | |||
| Mini-Mental State Examination, 26-item version | 25.00 | 23.00–26.00 | 21.00–26.00 |
| Montreal Cognitive Assessment | 25.00 | 23.75–27.00 | 20.00–29.00 |
| Balance | |||
| Mini-Balance Evaluation Systems Test | 20.00 | 19.00–22.00 | 15.00–26.00 |
| Severity of freezing of gait | |||
| CFOG-Qb | 24.50 | 17.25–34.75 | 10.00–50.00 |
| NFOG-Qb | 22.00 | 19.25–24.75 | 14.00–28.00 |
| %TF during unsupervised daily-living monitoring | 1.0 | 0.6–2.9 | 0.4–5.3 |
a
CFOG-Q = Characterizing Freezing of Gait Questionnaire; LEDD = levodopa equivalent daily dose; MDS-UPDRS = Movement Disorders Society Unified Parkinson’s Disease Rating Scale; NFOG-Q = New Freezing of Gait Questionnaire; PD = Parkinson disease; %TF = percentage of time spent frozen.
b
As shown on Figure 3, scores on the CFOG-Q and the NFOG-Q were not significantly correlated with each other.